Carlos José Molina Pérez

Dr. Carlos José Molina Pérez

Medical Research Division, INSTITUTO MEXICANO DEL SEGURO SOCIAL, Mexico City, Ciudad de México, Mexico
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in Hypertension
Verified
Journal Article
Closed access
PDF file
ALAlfredo Leaños-Miranda
Alfredo Leaños-Miranda
ANAna Graciela Nolasco-Leaños
Ana Graciela Nolasco-Leaños
RCReyes Ismael Carrillo-Juárez
Reyes Ismael Carrillo-Juárez
Carlos José Molina PérezCarlos José Molina Pérez
Carlos José Molina Pérez
LSLiliana Janet Sillas-Pardo
Liliana Janet Sillas-Pardo
KRKarla Leticia Ramírez-Valenzuela
Karla Leticia Ramírez-Valenzuela
Preeclampsia is characterized by angiogenic imbalance (AI), sFlt-1 (soluble fms-like tyrosine kinase-1)/PlGF (placental growth factor) is useful for its diagnosis and prediction of adverse outcomes, but the relationship among the degrees of AI as assessed by this ratio with the correct diagnosis, clinical characteristics, and outcomes in women with clinical diagnosis of preeclampsia are unclear. We studied 810 women with clinical diagnosis of preeclampsia. Patients were divided into 3 groups based on their degree of AI, evaluated by the sFlt-1/PlGF ratio: no AI (≤38), mild AI (>38–<85), and severe AI (≥85). Patients with no AI were more likely to have comorbidities and false significant proteinuria compared with patients with mild and severe AI ( P <0.001). The rates of preterm delivery, delivery within 14 days, and small-for-gestational-age infant were higher among patients with severe AI than in patients with no and mild AI ( P <0.001) and in patients with mild AI that in those with no AI ( P ≤0.01). The occurrence of any adverse maternal outcome (HELLP syndrome, elevated liver enzymes, thrombocytopenia, placental abruption, acute kidney injury) was only present in patients with severe AI. Interestingly, the frequency of misdiagnosis of preeclampsia was progressively lower as the degrees of AI increased (no AI: 100%, mild AI: 88.2%, and severe AI: 15.6%). We concluded that in women with clinical diagnosis of preeclampsia, severe AI is characterized by high frequency of true preeclampsia and preeclampsia-related adverse outcomes, in contrast, no and mild AI, are characterized by unnecessary early deliveries, often due to misdiagnosis.

1 January 2017 in Medicine
Verified
Journal Article
Open access
ALAlfredo Leaños-Miranda
Alfredo Leaños-Miranda
FMFrancisco Méndez-Aguilar
Francisco Méndez-Aguilar
KRKarla Leticia Ramírez-Valenzuela
Karla Leticia Ramírez-Valenzuela
MSMarilyn Serrano-Rodríguez
Marilyn Serrano-Rodríguez
PhD María Guadalupe Berumen-LechugaPhD María Guadalupe Berumen-Lechuga
PhD María Guadalupe Berumen-Lechuga
ICInova Campos-Galicia
Inova Campos-Galicia
Gestational hypertension (GH) and preeclampsia (PE) are characterized by an imbalance in angiogenic factors. However, the relationship among these factors with the severity of hypertensive disorders of pregnancy (HDP) and adverse outcomes are not fully elucidated. We examined whether these biomarkers are related with the severity of HDP and adverse outcomes. Using a cross-sectional design, serum concentrations of placental growth factor (PlGF), soluble fms-like tyrosine kinase-1 (sFlt-1), and soluble endoglin were determined in 764 pregnant women: 75 healthy pregnant, 83 with mild GH (mGH), 105 with severe GH (sGH), 122 with mild PE (mPE), and 379 with severe PE (sPE). All angiogenic factors’ concentrations were significantly different (P ≤ 0.041) in HDP than in healthy pregnancy. In addition, these factors were markedly different in sPE than in mPE, sGH, or mGH (P ≤ 0.027) and in patients with sGH that in those with mPE or mGH (P < 0.05). As compared to mGH and mPE, patients with sGH and sPE had higher rates of both preterm delivery at <34 weeks of gestation and small-for-gestational age infants. Moreover, patients with sPE had higher rates of adverse maternal outcomes (P < 0.001) when compared to patients with mGH, sGH, or mPE. In all cases, levels of sFlt-1/PlGF ratio were significantly higher in patients with sGH and sPE who had adverse perinatal and maternal outcomes than in those with sGH and sPE who did not (P ≤ 0.016). Circulating concentrations of angiogenic factors appear to be suitable markers to assess the severity of GH and PE, and adverse outcomes.

15 May 2015 in The Journal of Rheumatology
Verified
Journal Article
Closed access
PDF file
ALAlfredo Leaños-Miranda
Alfredo Leaños-Miranda
ICInova Campos-Galicia
Inova Campos-Galicia
PhD María Guadalupe Berumen-LechugaPhD María Guadalupe Berumen-Lechuga
PhD María Guadalupe Berumen-Lechuga
Carlos José Molina PérezCarlos José Molina Pérez
Carlos José Molina Pérez
YGYolanda García-Paleta
Yolanda García-Paleta
KRKarla Leticia Ramírez-Valenzuela
Karla Leticia Ramírez-Valenzuela
Objective To investigate whether angiogenic factors are associated with risk of developing preeclampsia in pregnant women with systemic lupus erythematosus (SLE). Methods We performed a nested case–control study within a cohort of SLE women with singleton pregnancies. The study included 42 patients with SLE who eventually developed preeclampsia and 75 normal SLE pregnancies. Serum samples were collected at 4-week intervals (from weeks 12 to 36). Serum samples were analyzed for soluble fms-like tyrosine kinase-1 (sFlt-1), placental growth factor (PlGF), and soluble endoglin (sEng). Results Women destined to develop preeclampsia had lower PlGF levels and higher sFlt-1 and sEng levels, and a higher sFlt-1/PlGF ratio than normal pregnancies. These changes became significant at 12 weeks in patients destined to develop either early onset (< 34 weeks, p ≤ 0.003) or late-onset preeclampsia (≥ 34 weeks, p ≤ 0.02). The risk to develop preeclampsia was higher among patients with PlGF concentration values in the lowest quartile or with sFlt-1 and sEng levels, and sFlt-1/PlGF ratio, in the highest quartile of the normal SLE pregnancies distribution. The OR were higher and appeared earlier in patients destined to develop early onset preeclampsia (OR ≥ 16.2, from Week 12 onward) than in patients who presented preeclampsia later (OR ≥ 8.9, from Week 24 onward). Conclusion Changes in circulating concentrations of sFlt-1, PlGF, sEng, and the sFlt-1/PlGF ratio precede the onset of preeclampsia in SLE pregnancies. The risk profile of circulating angiogenic factors for developing preeclampsia distinctly evolves depending on whether this condition is manifested earlier or later.

1 April 2021 in Fetal Diagnosis and Therapy
Verified
Journal Article
Closed access
PDF file
ALAlfredo Leaños-Miranda
Alfredo Leaños-Miranda
ANAna Graciela Nolasco-Leaños
Ana Graciela Nolasco-Leaños
RCReyes Ismael Carrillo-Juárez
Reyes Ismael Carrillo-Juárez
Carlos José Molina PérezCarlos José Molina Pérez
Carlos José Molina Pérez
IIIrma Isordia-Salas
Irma Isordia-Salas
KRKarla Leticia Ramírez-Valenzuela
Karla Leticia Ramírez-Valenzuela
Introduction: Amniotic fluid (AF) interleukin-6 (IL-6) concentration has been associated to preterm delivery and perinatal morbidity and mortality in women with preterm labor and intact membranes. Nevertheless, the clinical significance of this biomarker of intra-amniotic inflammation (IAI) is still unclear due in part to the paucity of large studies. Methods: AF IL-6 concentrations were determined in 452 consecutive women with preterm labor and intact membranes, categorized into 3 groups: 302 without IAI (IL-6 of <2.6 ng/mL), 64 with mild IAI (IL-6 of 2.6–11.2 ng/mL), and 86 with severe IAI (IL-6 of ≥11.3 ng/mL). Results: The severe IAI group had a short pregnancy duration from amniocentesis to delivery (median 3 days) than in without IAI group (median 45 days); meanwhile, the mild IAI group had a latency that was intermediate to the severe and without IAI groups (median 9.5 days). As compared to women without IAI, women with mild and severe IAI had higher rates of preterm delivery at both <34 and <37 weeks of gestation and perinatal morbidity and mortality. Furthermore, the risk of various individual adverse outcomes (short latency from amniocentesis to delivery [at ≤3 days, ≤7 days, and ≤14 days], preterm delivery at both <34 and <37 weeks of gestation, histologic chorioamnionitis, respiratory distress syndrome, and congenital sepsis) was higher in women with severe IAI (OR ≥ 2.8), compared with women without IAI. Conclusions: AF IL-6 concentrations appear to be suitable marker to assess the degree of IAI and are associated with increased risk of adverse outcomes.

1 September 2018 in Medicine
Verified
Journal Article
Open access
ALAlfredo Leaños-Miranda
Alfredo Leaños-Miranda
FMFrancisco Méndez-Aguilar
Francisco Méndez-Aguilar
Carlos José Molina PérezCarlos José Molina Pérez
Carlos José Molina Pérez
KRKarla Leticia Ramírez-Valenzuela
Karla Leticia Ramírez-Valenzuela
LSLiliana Janet Sillas-Pardo
Liliana Janet Sillas-Pardo
PhD María Guadalupe Berumen-LechugaPhD María Guadalupe Berumen-Lechuga
PhD María Guadalupe Berumen-Lechuga
Preeclampsia is characterized by an increased sensitivity to angiotensin II (Ang II). We herein assessed whether serum Ang II levels measured by a new developed bioassay are associated with preeclampsia, its severity, and the risk for developing this disease. Using a cross-sectional design, we studied 90 pregnant women (30 healthy pregnant and 60 with preeclampsia [30 with- and 30 without severe features]). We also used a nested case-control study with 30 women who eventually developed preeclampsia and 31 normotensive controls. Serum samples were collected at diagnosis of preeclampsia or at 4-week intervals (from weeks 12th to 36th). Ang II was measured using a bioassay. At diagnosis of preeclampsia, serum Ang II concentrations were significantly lower in preeclampsia without and with severe features (P = .001 and P < .001, respectively) than in healthy pregnancy. In addition, Ang II was different in preeclampsia with severe features than in those without severe features (P = .048). Women who subsequently developed preeclampsia had lower Ang II levels than women with normal pregnancies, and these changes became significant at 24 weeks onward. The risk to developing preeclampsia was higher among women with Ang II concentration values in the lowest quartile of the control distribution from 12 weeks onward (odds ratio ranging from 3.8 [95% CI 1.3–11.1] to 6.5 [95% CI 1.6–26.9]). We concluded that concentrations of Ang II are markedly diminished at diagnosis of preeclampsia and are closely associated with the severity of disease. Changes in circulating levels of Ang II precede the clinical presentation of preeclampsia.

7 September 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
PhD María Guadalupe Berumen-LechugaPhD María Guadalupe Berumen-Lechuga
PhD María Guadalupe Berumen-Lechuga
ALAlfredo Leaños-Miranda
Alfredo Leaños-Miranda
Carlos José Molina PérezCarlos José Molina Pérez
Carlos José Molina Pérez
LGLuis Rey García-Cortés
Luis Rey García-Cortés
SPSilvia Palomo-Piñón
Silvia Palomo-Piñón
Risk factors associated with severe–critical COVID-19 (coronavirus disease 2019) are based on findings in the general population. Pregnant women are at increased risk of severe–critical infection, and few reports are based on these women. A multicentric case–control study was conducted at the Mexican Institute of Social Security, State of Mexico, during the COVID-19 pandemic. We included pregnant women who were consecutively admitted to respiratory care units and were followed until 30 days after the resolution of pregnancy. A total of 758 pregnant women with a positive RT-PCR test for SARS-CoV-2 were enrolled from June 2020 to July 2021. We defined groups using the World Health Organization Severity Classification; cases were pregnant women with severe–critical COVID-19 (n = 123), and controls were subjects with non-severe COVID-19 (n = 635). Data was gathered from clinical files. A multivariate logistic regression analysis was used to adjust odds ratios and their 95% confidence intervals of factors associated with severe–critical COVID-19. Risk factors associated with severe–critical COVID-19 in pregnancy were non-vaccination (OR 10.18), blood type other than O (OR 6.29), maternal age > 35 years (OR 5.76), history of chronic hypertension (OR 5.12), gestational age at infection ≥ 31 weeks (OR 3.28), and multiparity (OR 2.80).